SCHEMBL6747115

SCHEMBL6747115

O=[N+]([O-])c1ccc(Cc2ccccc2)nc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
PKM P14618 1/20 0.56
MAPT P10636 5/20 0.50
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
LMNA P02545 3/20 0.50
ALDH1A1 P00352 6/20 0.49
NPBWR1 P48145 1/20 0.49
MCHR1 Q99705 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
AGTR1 P30556 1/20 0.49
KDM4E B2RXH2 2/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
RIPK1 Q13546 1/20 0.46
ATM Q13315 1/20 0.46
CYP19A1 P11511 1/20 0.43
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29151253 0.85 PKM (0.62) POLBSMN1; SMN2PKMMAPTMEN1
SCHEMBL31224820 0.81 POLB (0.52) POLBSMN1; SMN2PKMMAPTMEN1
SCHEMBL21908135 0.80 PKM (0.46) POLBSMN1; SMN2PKMMAPTMEN1
SCHEMBL1053453 0.77 KMT2A (0.60) POLBSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL510731 0.76 PKM (0.37) POLBSMN1; SMN2PKMMAPTMEN1
SCHEMBL267666 0.76 ALDH1A1 (0.70) POLBSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL4603302 0.75 CCNC (0.49) POLBSMN1; SMN2PKMMAPTMEN1
SCHEMBL15986775 0.75 MAPT (0.45) POLBSMN1; SMN2PKMMAPTMEN1
SCHEMBL3096453 0.75 MAPT (0.45) POLBSMN1; SMN2PKMMAPTMEN1
SCHEMBL4873349 0.75 MAPT (0.45) POLBSMN1; SMN2PKMMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12053459-B2 CDK2 inhibitors and methods of using the same CEDILLA THERAPEUTICS, INC. (MA) 2024-08-06 US disclosed
EP-4358954-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME Cedilla Therapeutics, Inc. (US) 2024-05-01 EP disclosed
CN-117561058-A CDK2 inhibitors and methods of use thereof 塞迪拉治疗股份有限公司 2024-02-13 CN disclosed
US-20230121337-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. 2023-04-20 US disclosed
WO-2022272106-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2022-12-29 WO disclosed
US-20040092737-A1 Benzopiperidine derivatives EISAI CO., LTD. 2004-05-13 US disclosed
US-6518423-B1 These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and EISAI CO., LTD. (JP) 2003-02-11 US disclosed
EP-0934941-A1 BENZOPIPERIDINE DERIVATIVES Eisai Co., Ltd. (JP) 1999-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092737-A1 Benzopiperidine derivatives HLA-DRB1, HRH1, HRH2 POLB 2838/4885SMN1; SMN2 4491/4885PKM 2494/4885
US-20230121337-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CDK2, CDK20, CDK2AP2 POLB 442/4885SMN1; SMN2 1898/4885PKM 1158/4885
US-12053459-B2 CDK2 inhibitors and methods of using the same CDK2, CDK20, CDK2AP2 POLB 442/4885SMN1; SMN2 1898/4885PKM 1158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.